Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 384 | 79 | 297 |
| Samples | 355 | 67 | 282 |
| Peptides | 288 | 58 | 239 |
Function
FBXL18 · F-box and leucine rich repeat protein 18
The protein encoded by this gene is a member of a family of proteins that contain an approximately 40-amino acid F-box motif. This motif is important for interaction with SKP1 and for targeting some proteins for degradation. The encoded protein has been shown to control the cellular level of FBXL7, a protein that induces mitotic arrest, by targeting it for polyubiquitylation and proteasomal degradation. Members of the F-box protein family, such as FBXL18, are characterized by an approximately 40-amino acid F-box motif. F-box proteins interact with SKP1 through the F box, and they interact with ubiquitination targets through other protein interaction domains. [provided by RefSeq, Mar 2016].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000382368 | Q96ME1 | 384 | 288 |
Gene Properties
Recurrent Mutations
All 288 amino-acid changes on canonical ENST00000382368 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in FBXL18 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in FBXL18 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 10/40 25% | 0/0 0% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Endometrial Carcinoma | 7/42 17% | 14/612 2% |
| Chondrosarcoma | 2/14 14% | 0/75 0% |
| Colorectal Carcinoma | 12/143 8% | 61/3239 2% |
| Melanoma | 2/210 1% | 33/1899 2% |
| Gastric Carcinoma | 1/74 1% | 28/1809 2% |
| Non-Small Cell Lung Carcinoma | 6/304 2% | 14/1390 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 9/752 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Neuroendocrine Tumour | 5/154 3% | 3/577 1% |
| Other Solid Cancers | 1/94 1% | 16/1515 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Mesothelioma | 2/62 3% | 0/165 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 7/810 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 11/1592 1% |
| Hepatocellular Carcinoma | 0/46 0% | 13/2210 1% |
| Head and Neck Carcinoma | 2/85 2% | 7/1574 0% |
| Non-Cancerous | 0/104 0% | 5/830 1% |
| Other Sarcomas | 0/69 0% | 4/699 1% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Esophageal Carcinoma | 0/23 0% | 4/769 1% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Glioma | 1/52 2% | 8/2127 0% |
| Biliary Tract Carcinoma | 0/54 0% | 4/950 0% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 8/2550 0% |
| Ovarian Carcinoma | 2/109 2% | 2/998 0% |
| Pancreatic Carcinoma | 1/89 1% | 5/1611 0% |
Mutation Distribution
Where FBXL18 is mutated · all tissues, split by cell line vs tissue
How many mutations in FBXL18 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 384 mutations in FBXL18
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|